SLRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SLRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Salarius Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Salarius Pharmaceuticals's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .
Salarius Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2023 was $1.48 Mil. It means Salarius Pharmaceuticals's Accounts Receivable declined by $1.48 Mil from Dec. 2022 to Dec. 2023 .
Salarius Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Salarius Pharmaceuticals's liquidation value for the three months ended in Mar. 2024 was $3.14 Mil.
The historical data trend for Salarius Pharmaceuticals's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Salarius Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Change In Receivables | Get a 7-Day Free Trial | - | -3.86 | 2.25 | - | 1.48 |
Salarius Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Change In Receivables | Get a 7-Day Free Trial | 1.48 | - | - | - | - |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Salarius Pharmaceuticals (NAS:SLRX) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Salarius Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0 | / | 0 | * | 91 |
= |
2. In Ben Graham's calculation of liquidation value, Salarius Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:
Salarius Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2024 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 4.373 | - | 1.234 | + | 0.75 * 0 | + | 0.5 * 0 |
= | 3.14 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Salarius Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Tess Burleson | director | 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021 |
Jonathan I Lieber | director | C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451 |
William K. Mcvicar | director | C/O INOTEK PHARMACEUTICALS CORPORATION, 131 HARTWELL AVENUE, SUITE 105, LEXINGTON MA 02421 |
Arnold C Hanish | director | 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119 |
Mark J Rosenblum | officer: Exec VP Finance, Interim CFO | 3990 SPRING VALLEY ROAD, APT. 1218, DALLAS TX 75244 |
David J. Arthur | director, officer: Chief Executive Officer | 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021 |
Scott Jordan | officer: Chief Financial Officer | 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021 |
Mccreedy Bruce J Jr. | director | 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021 |
Jonathan P Northrup | director | 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021 |
Pao-yu Chuang | officer: Controller | 2450 HOLCOMBE BLVD., SUITE J-608, HOUSTON TX 77021 |
Paul Lammers | director | 2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380 |
Boston Foundation, Inc. | 10 percent owner | 75 ARLINGTON STREET, BOSTON MA 02116 |
Christoph H Westphal | 10 percent owner | C/O ALNYLAM PHARMACEUTICALS, INC, 300 THIRD STREET, CAMBRIDGE MA 02142 |
Longwood Fund Ii, L.p. | 10 percent owner | 800 BOYLSTON STREET, SUITE 1555, BOSTON MA 02199 |
Roger D Tung | director | 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421 |
From GuruFocus
By sperokesalga sperokesalga • 05-11-2023
By Marketwired • 07-11-2023
By PurpleRose PurpleRose • 08-04-2022
By sperokesalga sperokesalga • 02-16-2023
By Value_Insider Value_Insider • 10-27-2022
By PurpleRose PurpleRose • 08-02-2022
By Stock market mentor Stock market mentor • 01-19-2023
By Marketwired • 11-07-2023
By sperokesalga sperokesalga • 05-16-2023
By Stock market mentor Stock market mentor • 01-27-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.